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633unknown criteria, many for as long as 4 to 5 days (mean
length of stay was 1.5 days), where it’s likely that they
underwent further investigation and risk modiﬁcation
despite an initial single negative troponin test. One
must assume hospitalization resulted in at least some
element of risk mitigation.
Furthermore, Bandstein et al. (1) report that 89%
(n ¼ 1,704) of those with an initial troponin<5 ng/l had
a second test. The total “low-risk population” who
had serial troponin tests was 1,917 patients. Thus, of
the 8,907 with an initial troponin <5 ng/l, only 19%
(n ¼ 1,704) had serial troponin testing? If correct, this
practice is inconsistent with either the European
Society of Cardiology or American Heart Association/
American College of Cardiology guidelines. Were
many of the initial troponins ordered inappropriately
for clinical scenarios later not considered to be
consistent with acute coronary syndrome?
Of patients with a second troponin test per-
formed, 3% (44 of 1,704) of levels were elevated. If
not an acute MI (AMI), what were their diagnoses?
And, if the 3% elevated second troponin rate was
applied to the single troponin low-risk cohort, an
additional 210 patients may have had an elevated
second troponin. Without a second troponin level,
how can it be claimed that an elevation wasn’t pre-
sent? By not using a standard AMI evaluation, is it
possible that missed AMI occurred and were not
found upon follow-up simply because the patient
didn’t die? Further, 39 patients were diagnosed with
MI by 30 days, implying a 2% (39 of 1,917) event rate.
If this event rate is also applied to the low-risk
population with a single troponin level, it is
possible that as many as 140 MIs were missed simply
because the patients weren’t tested nor dead in
1 year.
Ultimately, the suggested approach needs the
further support of an interventional trial with accu-
rate follow-up and in which data are collected
to measure the effect of the investigators’ recom-
mendation. Until this consideration is validated, the
“one and done” troponin strategy should only be
considered as hypothesis generating.*Louise Cullen, MB, BS
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Testing Time Is Also a Learning TimeWe would like to express our gratitude to Dr. Liu and
colleagues and Dr. Cullen and colleagues for their
letters regarding our recently published paper (1).
Firstly, we do agree that our ﬁndings need to be
validated in other settings than a university hospital,
with a different diversity of ethnicity, socioeconomic
status, and prevalence of cardiovascular disease.
All patients who were included in our study had
chest pain, an electrocardiogram (ECG) recorded, and
at least 1 troponin level measured (1). To our knowl-
edge, troponins are not used for any other reasons
than to conﬁrm or to exclude myocardial ischemia. In
addition, all patients had a clinical assessment made,
which we believe is common practice. Occasionally,
patients were assessed clinically after the troponin
level was available, and an explanation for the chest
pain other than a myocardial infarction (MI) would
lead to a discharge home. We believe that this is in
line with how patients with chest pain are assessed in
most emergency departments (ED).
Seventy-seven percent of admitted patients went
home the same or the next day. Naturally, diagnoses
such as pneumonia, pulmonary embolism, or atrial
ﬁbrillation may have necessitated longer hospital
stays. Our primary aim was not to investigate risk
mitigation in admitted versus discharged patients.
We believe that exercise tests, stress echocardio-
grams, or coronary angiograms by themselves have
no impact on prognosis. We do acknowledge that
there may have been patients discharged who may
have had a second troponin >14 ng/l if measured.
However, the risk of all-cause mortality was not
higher in patients discharged versus admitted, and
there were only 2 cardiovascular deaths within 12
months in 8,907 patients with troponins <5 ng/l,
which indicates an excellent long-term prognosis.
In a random sample of 100 patients, the mean time
to measurement of troponins was 2.5 h. Thus, most
patients had their ﬁrst troponin level evaluated
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634before 3 h, and we do agree that if in doubt whether to
admit or to discharge the patient, it may be appro-
priate to have a second troponin measured.
Fifteen patients with troponins <5 ng/l, and normal
ECG developed MI. Of these patients, 1 came back at
day 18, and 3 developed ST-segment elevation within
1 h of arrival. Another 3 patients had sinus tachycardia
and would not be sent home after assessment, we
believe, by any physician. That leaves us with 8 of
1,697 (0.47%) patients, which yields a negative pre-
dictive value of 99.5%, for patients admitted.
We believe that our results, together with a robust
clinical assessment, is helpful for any ED physician, to
decide, if in doubt, which patient with chest pain to
admit or to send home.Nadia Bandstein, MD
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